RGNX – REGENXBIO Inc.
REGENXBIO Inc.RGNX
$8.18Name : REGENXBIO Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $410,312,096.00
EPSttm : -3.09
REGENXBIO Inc.
$8.18
2.63%$0.21Float Short %
11.43
Margin Of Safety %
Put/Call OI Ratio
0.29
EPS Next Q Diff
0.24
EPS Last/This Y
3.61
EPS This/Next Y
0.26
Price
8.18
Target Price
33.92
Analyst Recom
1.38
Performance Q
11.6
Relative Volume
2.83
Beta
1.08
Ticker: RGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | RGNX | 6.33 | 0.48 | 11.00 | 3866 |
| 2025-04-15 | RGNX | 6.55 | 0.48 | 0.00 | 3879 |
| 2025-04-16 | RGNX | 6.16 | 0.48 | 999.99 | 3891 |
| 2025-04-17 | RGNX | 5.92 | 0.46 | 0.00 | 3834 |
| 2025-04-18 | RGNX | 5.94 | 0.46 | 0.00 | 3834 |
| 2025-04-21 | RGNX | 6.67 | 0.55 | 0.00 | 2744 |
| 2025-04-22 | RGNX | 7.82 | 0.51 | 0.00 | 2862 |
| 2025-04-23 | RGNX | 8.88 | 0.46 | 0.00 | 3083 |
| 2025-04-24 | RGNX | 9.22 | 0.39 | 0.00 | 3449 |
| 2025-04-25 | RGNX | 9.16 | 0.38929146537842 | 0.17647058823529 | 3451 |
| 2025-04-28 | RGNX | 9.13 | 0.38918046023415 | 0 | 3441 |
| 2025-04-29 | RGNX | 9.41 | 0.39 | 0.00 | 3448 |
| 2025-04-30 | RGNX | 9.6 | 0.38 | 0.00 | 3510 |
| 2025-05-01 | RGNX | 9.83 | 0.36 | 0.00 | 3650 |
| 2025-05-02 | RGNX | 10.39 | 0.36 | 0.01 | 3658 |
| 2025-05-05 | RGNX | 9.75 | 0.32 | 2.00 | 3944 |
| 2025-05-06 | RGNX | 7.91 | 0.33 | 0.16 | 3923 |
| 2025-05-07 | RGNX | 7.24 | 0.33 | 0.11 | 3924 |
| 2025-05-08 | RGNX | 7.15 | 0.31 | 0.05 | 4246 |
| 2025-05-09 | RGNX | 7.53 | 0.31 | 0.02 | 4269 |
| 2025-05-12 | RGNX | 7.97 | 0.31 | 0.01 | 4293 |
| 2025-05-13 | RGNX | 8.19 | 0.29 | 0.00 | 4434 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | RGNX | 6.33 | 125.4 | 349.5 | -0.98 |
| 2025-04-15 | RGNX | 6.55 | 125.4 | 339.1 | -0.98 |
| 2025-04-16 | RGNX | 6.15 | 125.4 | 318.0 | -0.98 |
| 2025-04-17 | RGNX | 5.94 | 125.4 | 322.8 | -0.98 |
| 2025-04-18 | RGNX | 5.94 | 125.4 | 331.0 | -0.98 |
| 2025-04-21 | RGNX | 6.66 | 136.3 | 360.0 | -0.98 |
| 2025-04-22 | RGNX | 7.82 | 136.3 | 368.2 | -0.98 |
| 2025-04-23 | RGNX | 8.87 | 136.3 | 356.5 | -0.98 |
| 2025-04-24 | RGNX | 9.22 | 136.3 | 338.1 | -0.98 |
| 2025-04-25 | RGNX | 9.15 | 136.3 | 330.3 | -0.98 |
| 2025-04-28 | RGNX | 9.13 | 136.3 | 330.7 | -0.98 |
| 2025-04-29 | RGNX | 9.41 | 136.3 | 336.4 | -0.98 |
| 2025-04-30 | RGNX | 9.61 | 136.3 | 334.7 | -0.98 |
| 2025-05-01 | RGNX | 9.83 | 136.3 | 335.1 | -0.98 |
| 2025-05-02 | RGNX | 10.40 | 136.3 | 340.8 | -0.98 |
| 2025-05-05 | RGNX | 9.76 | 136.3 | 321.0 | -0.98 |
| 2025-05-06 | RGNX | 7.90 | 136.3 | 298.9 | -0.98 |
| 2025-05-07 | RGNX | 7.24 | 136.3 | 314.7 | -0.98 |
| 2025-05-08 | RGNX | 7.14 | 136.3 | 328.2 | -0.98 |
| 2025-05-09 | RGNX | 7.52 | 136.3 | 342.0 | -0.98 |
| 2025-05-12 | RGNX | 7.97 | 136.3 | 343.4 | -0.98 |
| 2025-05-13 | RGNX | 8.18 | 136.3 | 336.1 | -0.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-15 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-16 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-17 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-18 | RGNX | 0.00 | -4.97 | 11.54 |
| 2025-04-21 | RGNX | 0.00 | -6.20 | 11.54 |
| 2025-04-22 | RGNX | 0.00 | -6.20 | 11.54 |
| 2025-04-23 | RGNX | 0.00 | -6.20 | 11.54 |
| 2025-04-24 | RGNX | 0.00 | -6.20 | 11.54 |
| 2025-04-25 | RGNX | 0.00 | -6.20 | 11.54 |
| 2025-04-28 | RGNX | 0.00 | -5.95 | 11.61 |
| 2025-04-29 | RGNX | 0.00 | -5.95 | 11.61 |
| 2025-04-30 | RGNX | 0.00 | -5.95 | 11.61 |
| 2025-05-01 | RGNX | 0.00 | -5.95 | 11.61 |
| 2025-05-02 | RGNX | 0.00 | -5.95 | 11.61 |
| 2025-05-05 | RGNX | 0.00 | -1.36 | 11.61 |
| 2025-05-06 | RGNX | 0.00 | -1.36 | 11.61 |
| 2025-05-07 | RGNX | 0.00 | -1.36 | 11.61 |
| 2025-05-08 | RGNX | 0.00 | -1.36 | 11.61 |
| 2025-05-09 | RGNX | 0.00 | -1.36 | 11.61 |
| 2025-05-12 | RGNX | 0.00 | 3.05 | 11.43 |
| 2025-05-13 | RGNX | 0.00 | 3.05 | 11.43 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.01
Avg. EPS Est. Current Quarter
0.34
Avg. EPS Est. Next Quarter
-0.77
Insider Transactions
Institutional Transactions
3.05
Beta
1.08
Average Sales Estimate Current Quarter
105
Average Sales Estimate Next Quarter
35
Fair Value
Quality Score
39
Growth Score
31
Sentiment Score
4
Actual DrawDown %
83.7
Max Drawdown 5-Year %
-89.4
Target Price
33.92
P/E
Forward P/E
PEG
P/S
2.62
P/B
1.5
P/Free Cash Flow
EPS
-3.14
Average EPS Est. Cur. Y
-0.98
EPS Next Y. (Est.)
-0.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-100.62
Relative Volume
2.83
Return on Equity vs Sector %
-111.2
Return on Equity vs Industry %
-94.2
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.57
EBIT Estimation
336.1
REGENXBIO Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 353
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
stock quote shares RGNX – REGENXBIO Inc. Stock Price stock today
news today RGNX – REGENXBIO Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RGNX – REGENXBIO Inc. yahoo finance google finance
stock history RGNX – REGENXBIO Inc. invest stock market
stock prices RGNX premarket after hours
ticker RGNX fair value insiders trading